Press Release

Toray and ASKA Conclude Business Collaboration
Agreement for Adhesion BarrierTOKYO, October 5th, 2021 – ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku,Tokyo/ Representative Director: Sohta Yamaguchi), a subsidiary of ASKA Pharmaceutical Holdings
Co., Ltd. (Headquarter: Minato-ku, Tokyo/ Representative Director: Takashi Yamaguchi), and Toray
Industries, Inc. (head office: Chuo-ku, Tokyo/ President: Akihiro Nikkaku; hereinafter referred toas “Toray”) announced today that the two companies have signed a business collaborationagreement to develop and commercialize an adhesion barrier (Toray Development Code: TRM-270C;
hereinafter referred to as “Product”) in Japan. Toray has been developing the Product in collaboration
with Nanotheta Co., Ltd. (head office: Shinjuku-ku, Tokyo/ President: Shinya Otsubo).
The impact of this agreement on consolidated results for FY 2021 will be minor.
For details, please see attached sheet.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

Toray and ASKA Conclude Business Collaboration
Agreement for Adhesion Barrier
Tokyo, Japan, October 5, 2021 – Toray Industries, Inc. (head office: Chuo-ku, Tokyo; President
Akihiro Nikkaku; hereinafter referred to as “Toray”) and ASKA Pharmaceutical Co., Ltd. (headoffice: Minato-ku, Tokyo; President Sohta Yamaguchi; hereinafter referred to as “ASKA”)
announced today that the two companies have signed a business collaboration agreement todevelop and commercialize an adhesion barrier * (Toray Development Code: TRM-270C;
hereinafter referred to as “Product”) in Japan. Toray has been developing the Product incollaboration with Nanotheta Co., Ltd. (head office: Shinjuku-ku, Tokyo; President Shinya Otsubo).
Under the agreement, Toray and ASKA will jointly develop the Product to obtain a marketing
approval of the Product in Japan. Upon the approval, Toray will manufacture the Product, as
ASKA will exclusively market the Product in Japan.
The Product is used during medical procedures such as laparotomies and laparoscopies inobstetrics and gynecology as well as in gastroenterology procedures. It has a laminated structurethat comprises anti-adhesive layers as well as supportive layers which are made of biodegradable
polymers and water-soluble polymers respectively. By utilizing a laminated structure withdifferent properties provides the necessary flexibility and adhesiveness to target organs. The
expected benefits of such properties are good operability particularly during laparoscopic
surgeries with an excellent anti-adhesive effect.
In Toray’s medium-term management program “Project AP-G 2022”, business expansion in Life
Innovation field is one of its basic policies. As part of such policy, Toray is focusing on developing
and commercializing medical devices that apply its core technologies based on polymer chemistry
and nanotechnology. ASKA, since its establishment in 1920, has endeavored to solve unmet
medical needs by developing pharmaceuticals, primarily new drugs and medical-related products
as a specialty pharmaceutical company that focuses on internal medicine, obstetrics andgynecology, and urology. Thus, the above agreement was concluded based on the alignment of
the two companies’ business policy.
By the commercialization of the above Product, Toray and ASKA hope to improve the prognosesof patients who undergo surgery in obstetrics and gynecology as well as gastroenterology
interventions.
*Adhesion barrier
When tissues are sutured together in surgery, it is normal for the sutured tissues to adhere andheal spontaneously. However, during the healing process after surgery, postoperative adhesion
can occur, whereby tissues that should be separated, can adhere to one another. These
postoperative adhesions can cause complications such as, small bowel obstruction, secondaryinfertility, and chronic pelvic pain. Adhesion barriers are applied to areas effected by surgeries toprevent such adhesions.

Contact: Toray Industries, Inc. Head Office Corporate Communications Dept.
Tel: Tokyo +81-3-3245-5179 / Osaka +81-6-7688-3085
ASKA Pharmaceutical Co., Ltd. Corporate Planning Dept.
Tel: +81-3-5484-8366－1/2－About Toray
Toray is a leading global company in innovative technologies and advancedmaterials. Since its foundation in 1926, the Company has contributed tosociety through the creation of new value and addressed global challenges
by delivering high value-added products including fibers and textiles, resins
and films, and carbon fiber composite materials. It operates in 29 countries
and regions with about 46,000 employees worldwide.
For more information, please visit our website at www.toray.com.
About ASKA
ASKA celebrated its 100th anniversary in 2020 and inaugurated a holding
company structure in April 2021. ASKA contributes to the medical community
as a specialty pharma company emphasizing in three therapeutic areas ofinternal medicine, obstetrics and gynecology, and urology. ASKA is focusing
on developing new drugs as well as medical devices to address unmet
medical needs and to offer new treatment methods.
For more information, please visit our website at www.aska-pharma-hd.co.jp.
Press Contact
TORAY Corporate Communications Department
Email: newsrelease.toray.mb@mail.toray
ASKA Pharmaceutical Co., Ltd.
Corporate Planning Department
Email: kouhou@aska-pharma.co.jp－2/2－